Holen Sie sich die Stockscreener-App
49.82
4.12%
-2.14
Handel nachbörslich:
49.82
Schlusskurs vom Vortag:
$51.96
Offen:
$50.09
24-Stunden-Volumen:
531.56K
Relative Volume:
1.08
Marktkapitalisierung:
$3.15B
Einnahmen:
$112.53M
Nettoeinkommen (Verlust:
$-258.91M
KGV:
-11.51
EPS:
-4.33
Netto-Cashflow:
$-124.42M
1W Leistung:
-6.86%
1M Leistung:
-4.92%
6M Leistung:
+2.55%
1J Leistung:
+21.84%
1-Tages-Spanne:
$49.62
$50.74
1-Wochen-Bereich:
$48.23
$55.21
52-Wochen-Spanne:
$35.17
$68.58
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Firmenname
Rhythm Pharmaceuticals Inc
Sektor
Branche
Telefon
857-264-4280
Adresse
222 BERKELEY STREET, BOSTON, MA
Vergleichen Sie RYTM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
49.82 | 3.15B | 112.53M | -258.91M | -124.42M | -4.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-05 | Fortgesetzt | Stifel | Buy |
| 2025-01-02 | Eingeleitet | Jefferies | Buy |
| 2024-12-20 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-21 | Eingeleitet | Guggenheim | Buy |
| 2024-09-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-17 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-05-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-08-08 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-05 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-06-17 | Bestätigt | Needham | Buy |
| 2022-03-02 | Fortgesetzt | Stifel | Buy |
| 2022-02-17 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | Fortgesetzt | Goldman | Neutral |
| 2021-08-04 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-08-04 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-01-08 | Eingeleitet | Goldman | Sell |
| 2019-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2019-07-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-03-13 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-09-07 | Fortgesetzt | Morgan Stanley | Overweight |
| 2018-06-25 | Bestätigt | Needham | Buy |
| 2018-06-15 | Bestätigt | Needham | Buy |
| 2017-10-30 | Eingeleitet | BofA/Merrill | Buy |
| 2017-10-30 | Eingeleitet | Needham | Buy |
Alle ansehen
Rhythm Pharmaceuticals Inc Aktie (RYTM) Neueste Nachrichten
Corebridge Financial Inc. Has $1.52 Million Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
(RYTM) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives $69.46 Average Target Price from Analysts - Defense World
Teacher Retirement System of Texas Increases Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - The AM Reporter
When Will Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Breakeven? - simplywall.st
Teacher Retirement System of Texas Has $761,000 Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Rhythm Pharma ends RareStone licensing deal in China - MSN
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Equities Analysts Offer Predictions for RYTM Q1 Earnings - Defense World
Q2 Earnings Estimate for RYTM Issued By HC Wainwright - Defense World
Swiss National Bank Has $5.05 Million Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Rhythm Pharmaceuticals (NASDAQ:RYTM) Given Buy Rating at HC Wainwright - Defense World
Rhythm Pharmaceuticals corporate controller sells shares for $18,655 By Investing.com - Investing.com Australia
Rhythm Pharmaceuticals corporate controller sells shares for $18,655 - Investing.com India
Analyst Expectations For Rhythm Pharmaceuticals's Future - Benzinga
Is Rhythm Pharmaceuticals (RYTM) a Worst High-Risk High-Reward Growth Stock to Buy? - MSN
(RYTM) Proactive Strategies - news.stocktradersdaily.com
Rhythm Pharma stock down as licensing deal ends (RYTM:NASDAQ) - Seeking Alpha
Victory Capital Management Inc. Reduces Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Rhythm Pharmaceuticals regains rights to obesity drug in China By Investing.com - Investing.com South Africa
Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd. - MarketScreener
Rhythm Pharmaceuticals regains rights to obesity drug in China - Investing.com India
Rhythm Pharmaceuticals Reacquires Licensing Rights to - GlobeNewswire
Strategic Win: Rhythm Pharmaceuticals Reclaims IMCIVREE Rights in China, Strengthens Global Position - StockTitan
Rhythm Pharmaceuticals Announces Orphan Drug Designation - GlobeNewswire
Rhythm Pharmaceuticals receives orphan drug status in Japan By Investing.com - Investing.com Australia
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted To Setmelanotide For Treatment Of Hypothalamic Obesity In Japan - Marketscreener.com
Rhythm Pharmaceuticals receives orphan drug status in Japan - Investing.com
Rhythm Pharmaceuticals Receives Orphan-Drug Designation in Japan for Obesity Treatment - MarketWatch
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan - The Manila Times
Breakthrough for Rare Obesity: Rhythm's Drug Wins Special Status in Japan - StockTitan
Rhythm Pharmaceuticals EVP sells shares worth $3.86 million By Investing.com - Investing.com South Africa
Charles Schwab Investment Management Inc. Has $24.65 Million Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Rhythm Pharmaceuticals (NASDAQ:RYTM) Given New $66.00 Price Target at Needham & Company LLC - Defense World
Rhythm Pharmaceuticals EVP sells shares worth $3.86 million - Investing.com India
Needham raises Rhythm Pharma stock target to $66, maintains buy By Investing.com - Investing.com UK
Rhythm Pharmaceuticals and Raymond A. Wood Foundation Launch Research Collaboration on Fatigue in Craniopharyngioma Patients - Nasdaq
Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration - GlobeNewswire
Bank of New York Mellon Corp Sells 680 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Insider Sell Alert: EVP, Head of North America Jennifer Lee Sells Shares of Rhythm Pharmaceuticals Inc (RYTM) - GuruFocus.com
How To Trade (RYTM) - Stock Traders Daily
SBI Securities Co. Ltd. Invests $37,000 in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Stifel maintains Buy on Rhythm Pharmaceuticals, $78 target By Investing.com - Investing.com Canada
Stifel maintains Buy on Rhythm Pharmaceuticals, $78 target - Investing.com India
Reviewing Wave Life Sciences (NASDAQ:WVE) & Rhythm Pharmaceuticals (NASDAQ:RYTM) - Defense World
Finanzdaten der Rhythm Pharmaceuticals Inc-Aktie (RYTM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):